Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Merck Serono

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    - PMLiVE

    Novartis to acquire Avidity Biosciences in deal worth $12bn

    The acquisition will expand Novartis’ neuroscience pipeline

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Novartis announces new data supporting MS therapy Kesimpta

    The latest trial results reinforce the drug's long-term efficacy and safety profile

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    - PMLiVE

    Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

    Novartis will gain cardiovascular treatment option pacibekitug

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links